Scholarlink

Introduction <p>As the treatment landscape for alopecia areata (AA) expands, it is crucial to understand how treatment properties impact clinician decision-making. The objective of the study was to understand how clinicians treating AA make decisions and evaluate the relative importance (RI) of treatment attributes.</p> Methods <p>An online discrete choice experiment (DCE) was conducted among clinicians treating AA recruited through M3 Global Research’s US panel from February to March 2024. Treatment selection was evaluated using a series of 10&#xa0;hypothetical binary choices. Preference weights from the DCE were estimated from conditional logistic regression models and were used to calculate willingness to trade off and attributes’ RI. For preference of prescription drug profile, clinicians chose among three blinded profiles of Janus kinase (JAK) inhibitor treatments approved for use in AA based on data from phase&#xa0;2b–3 pivotal studies. Drug profile&#xa0;A was based on baricitinib 4-mg data, profile B on ritlecitinib 50-mg data, and profile C on deuruxolitinib 8-mg data. These blinded profiles were ranked as most and least preferred.</p> Results <p>Of the 249 screened clinicians, 155 were eligible for analysis (129 dermatologists, 15 physician assistants, and 11 nurse practitioners). Clinicians were predominantly White (75.5%) and male (57.4%), with a mean age of 47.3&#xa0;years. Approximately 50% of the clinicians had been practicing for over 15&#xa0;years, and the majority were in office-based practices (82%), seeing a mean of 38.8 patients with AA per month. The RI in decreasing order was scalp hair regrowth (52.7%), initial hair growth (31.5%), and medication frequency (15.8%). For the blinded treatment profiles, drug profile&#xa0;C was most preferred (72.2%) and drug profile&#xa0;B was least preferred (81.9%).</p> Conclusion <p>Our study demonstrated that, regarding JAK inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset regardless of once-daily or twice-daily dosing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • James Q. Del Rosso,
  • David Pariser,
  • Neal Bhatia,
  • Kathleen L. Deering,
  • Qing Harshaw,
  • Victoria Barghout,
  • Thomas J. Ferro

摘要

Introduction

As the treatment landscape for alopecia areata (AA) expands, it is crucial to understand how treatment properties impact clinician decision-making. The objective of the study was to understand how clinicians treating AA make decisions and evaluate the relative importance (RI) of treatment attributes.

Methods

An online discrete choice experiment (DCE) was conducted among clinicians treating AA recruited through M3 Global Research’s US panel from February to March 2024. Treatment selection was evaluated using a series of 10 hypothetical binary choices. Preference weights from the DCE were estimated from conditional logistic regression models and were used to calculate willingness to trade off and attributes’ RI. For preference of prescription drug profile, clinicians chose among three blinded profiles of Janus kinase (JAK) inhibitor treatments approved for use in AA based on data from phase 2b–3 pivotal studies. Drug profile A was based on baricitinib 4-mg data, profile B on ritlecitinib 50-mg data, and profile C on deuruxolitinib 8-mg data. These blinded profiles were ranked as most and least preferred.

Results

Of the 249 screened clinicians, 155 were eligible for analysis (129 dermatologists, 15 physician assistants, and 11 nurse practitioners). Clinicians were predominantly White (75.5%) and male (57.4%), with a mean age of 47.3 years. Approximately 50% of the clinicians had been practicing for over 15 years, and the majority were in office-based practices (82%), seeing a mean of 38.8 patients with AA per month. The RI in decreasing order was scalp hair regrowth (52.7%), initial hair growth (31.5%), and medication frequency (15.8%). For the blinded treatment profiles, drug profile C was most preferred (72.2%) and drug profile B was least preferred (81.9%).

Conclusion

Our study demonstrated that, regarding JAK inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset regardless of once-daily or twice-daily dosing.